Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.

ABSTRACT:

Background

Accessible biomarkers are needed for immunotherapy in advanced non-small-cell lung cancer (NSCLC). We previously described a multivariate risk prediction model, the iSEND, which categorises advanced NSCLC patients treated with nivolumab into Good, Intermediate or Poor groups. This model was developed by using only clinical and analytical variables (sex, ECOG-performance status, neutrophil-to-lymphocyte ratio [NLR] and post-treatment delta NLR).

Methods

An international database of 439 patients who received post-platinum PD-1/L1 monotherapies was collected for validation. Performance of the iSEND to different PD-L1 groups was compared by using time-dependent positive predictive value (PPV) for their mortality events.

Results

Median follow-up was 18.2 months

SUBMITTER: Park W 

PROVIDER: S-EPMC7000664 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature